With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.76003-29-7,1-Boc-3-Oxopiperazine,as a common compound, the synthetic route is as follows.
To a solution of 50.0 mmol of 5 and 60.0 mmol of 7 in 50.0 mL of 1,4-dioxane was added 0.500 mmol of copper (I) iodide followed by the addition of 100 mmol of K3P04 and 5 mmol of trans-cyclohexanediamine, then the resulting mixture was stirred at 100 C for 16 h. The reaction mixture was cooled to room temperature and diluted with 500 mL of H20. The resulting aqueous solution was extracted with CHC13. The organic phase was washed with saturated NaCl, dried over MgS04 and concentrated in vacuo. The crude product was purified by column chromatography to give 43.4 mmol of 8. ?H NMR (400 MHz, CDCl3) No. 7.97-8.00 (m, 1H), 7.35-7.40 (m, 1H), 6.50-6.54 (m, 1H), 4.54 (br s, 2H), 4.24 (s, 2H), 3.65-3.69 (m, 2H), 3.75-3.80 (m, 2H), 1.50 (s, 9H) ; MS m/z: 293 (M+1)., 76003-29-7
The synthetic route of 76003-29-7 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; ICAGEN, INC.; ASTELLAS PHARMA INC.; WO2005/100349; (2005); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics